Last reviewed · How we verify
NCT04342429
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
NA trial testing Proton-beam Therapy for Small Cell Lung Cancer in Small-cell Lung Cancer in 30 participants. Currently enrolling.
27 May 2026
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 19 March 2020 |
| Primary completion | 27 May 2026 |
| Estimated completion | 27 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Proton-beam Therapy for Small Cell Lung Cancer
Conditions studied
- Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →
Sponsor
Emory University
Who can join
18 and older, any sex, with Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04342429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Small-cell Lung Cancer
Currently open trials in the same condition.
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT · Phase 3 · recruiting
- NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi · Phase 3 · recruiting
- NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers · Phase 2 · recruiting
- NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab · NA · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04342429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 15 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04342429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing